Every one of those 1 sits in a single category, health-it. DIAGNOS Inc. is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. They are less corroborated than the beat average, carrying 2 original sources each against 4.7 for the same window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about CARA
Every one of those 1 sits in a single category, health-it. DIAGNOS Inc. is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. They are less corroborated than the beat average, carrying 2 original sources each against 4.7 for the same window. The 5 average consequence score is below the beat benchmark of 5.6 in the same window. We currently track 1 Healthcare story that mention CARA, all published on February 26, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 41 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering CARA. Shared-story counts are live from our verified record — not editorial picks.
DIAGNOS Inc. (OTCMKTS: DGNOF) has released its latest financial results, highlighting the company's ongoing efforts to scale its AI-driven retinal screening platform. The results come as the healthcare industry increasingly adopts automated diagnostic tools to address the global rise in diabetic retinopathy and other vision-threatening conditions.